These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34338402)

  • 1. Semaglutide single-dose pen-injector: Post hoc analysis of summative usability testing for weight management.
    Klonoff DC; Bassock S; Engels E; Frederiksen M; Marber M; Qvist M; Sparre T; Snitker S
    Diabetes Obes Metab; 2021 Nov; 23(11):2590-2594. PubMed ID: 34338402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the usability and safety of the semaglutide single-dose pen-injectors through summative (human factors) usability testing.
    Klonoff DC; Bassock S; Dwyer A; Engels E; Qvist M; Sparre T; Snitker S
    J Diabetes Investig; 2021 Jun; 12(6):978-987. PubMed ID: 33034163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.
    Snitker S; Egebjerg C; Frederiksen M; Sparre T
    Diabetes Obes Metab; 2022 Nov; 24(11):2273-2276. PubMed ID: 35791625
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes.
    LaRue S; Malloy J
    J Diabetes Sci Technol; 2015 Jul; 9(4):815-21. PubMed ID: 25759181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.
    Fujioka K; Sparre T; Sun LY; Krogsgaard S; Kushner RF
    J Diabetes Sci Technol; 2015 Jul; 10(1):164-74. PubMed ID: 26183599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semaglutide: First Global Approval.
    Dhillon S
    Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usability engineering study in the European Union of a redesigned follitropin alfa pen injector for infertility treatment.
    Jeannerot F; Stüdeli T; Gunther-LaVergne L; Hirning D; Schertz J
    Expert Opin Drug Deliv; 2016 Sep; 13(9):1221-9. PubMed ID: 27329677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
    Matfin G; Van Brunt K; Zimmermann AG; Threlkeld R; Ignaut DA
    J Diabetes Sci Technol; 2015 Apr; 9(5):1071-9. PubMed ID: 25901022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
    Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
    Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
    Scheen AJ
    Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
    Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
    Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
    Lau DCW; Batterham RL; le Roux CW
    Expert Rev Clin Pharmacol; 2022 Mar; 15(3):251-267. PubMed ID: 35466848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes.
    Pohlmeier H; Berard L; Brulle-Wohlhueter C; Wu J; Dahmen R; Nowotny I; Klonoff D
    J Diabetes Sci Technol; 2017 Mar; 11(2):263-269. PubMed ID: 27664062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanism.
    Zijlstra E; Coester HV; Heise T; Plum-Mörschel L; Rasmussen O; Rikte T; Pedersen LK; Qvist M; Sparre T
    Diabetes Obes Metab; 2018 May; 20(5):1140-1147. PubMed ID: 29369493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semaglutide as a promising antiobesity drug.
    Christou GA; Katsiki N; Blundell J; Fruhbeck G; Kiortsis DN
    Obes Rev; 2019 Jun; 20(6):805-815. PubMed ID: 30768766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
    Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.